Subgroup analysis of Asian patients: Compared with zoledronic acid, there were fewer first SREs in the Angarve® group.18 <br>Asian data: time to first occurrence of SREs
Subgroup Analysis of Asian Patients: The first SREs18 were less common in the ® group than pyrethroid acid<br>Asian data: to the time when SREs first occurred
Subgroup analysis of Asian patients: compared with zoledronic acid, the first sres18 was less common in the angravir? Group<br>Asian data: time to first SREs occurrence<br>